Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

FDA Revamps to Meet New Challenges

Added responsibilities and outside concerns prompt overhaul of agency's structure.
Dec 2, 2011

Added responsibilities and outside concerns prompt overhaul of agency's structure.

Drug Shortages Create Crisis for Manufacturers, Regulators

Clamor mounts over compromised care and rising costs due to lack of crucial therapies.
Nov 2, 2011

Clamor mounts over compromised care and rising costs due to lack of crucial therapies.

Global Health Challenges Spur Vaccine Development

Manufacturers fund research and reduce prices to tackle diseases.
Oct 2, 2011

Manufacturers fund research and reduce prices to tackle diseases.

Washington Report: Manufacturers and FDA Gear Up for User-Fee Action

PDUFA renewal legislation sets stage for new policies affecting revenue, research, and oversight.
Sep 2, 2011

PDUFA renewal legislation sets stage for new policies affecting revenue, resarch, and oversight.

Washington Report: FDA Maps Strategy to Counter Supply-Chain Threats

Rising imports and overseas production spur realignment of enforcement.
Aug 2, 2011

Rising imports and overseas production spur realignment of enforcement.

FDA and Manufacturers Ponder Biosimilars Pathway

Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.
Jul 2, 2011

Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.

Safety Concerns and Shortages Challenge Pharma

Industry struggles to curb drug abuse, diversion, and disruptions in supply.
Jun 2, 2011

Industry struggles to curb drug abuse, diversion, and disruptions in supply.

Experts Ponder Ways to Fill Pharma Pipeline

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.
May 2, 2011

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.

Health-Reform Controversies

Courts and Congress seek to reshape policies and programs.
Apr 2, 2011

Courts and Congress seek to reshape policies and programs.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here